We assign a fundamental rating of 3 out of 10 to CGEN. CGEN was compared to 524 industry peers in the Biotechnology industry. While CGEN seems to be doing ok healthwise, there are quite some concerns on its profitability. CGEN has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

CGEN had negative earnings in the past year.
In the past year CGEN has reported a negative cash flow from operations.
In the past 5 years CGEN always reported negative net income.
In the past 5 years CGEN reported 4 times negative operating cash flow.

1.2 Ratios

CGEN has a better Return On Assets (-18.17%) than 77.52% of its industry peers.
CGEN has a Return On Equity of -38.52%. This is in the better half of the industry: CGEN outperforms 71.62% of its industry peers.

		Industry Rank	Sector Rank
ROA	-18.17%
ROE	-38.52%
ROIC	N/A

ROA(3y)-21.2%

ROA(5y)-22.19%

ROE(3y)-32.63%

ROE(5y)-30.94%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

CGEN has a better Gross Margin (62.33%) than 78.86% of its industry peers.
In the last couple of years the Gross Margin of CGEN has declined.
The Profit Margin and Operating Margin are not available for CGEN so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	62.33%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-6.9%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CGEN has been increased compared to 1 year ago.
The number of shares outstanding for CGEN has been increased compared to 5 years ago.
There is no outstanding debt for CGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -4.32, we must say that CGEN is in the distress zone and has some risk of bankruptcy.
CGEN has a Altman-Z score (-4.32) which is comparable to the rest of the industry.
There is no outstanding debt for CGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-4.32

ROIC/WACCN/A

WACC8.73%

2.3 Liquidity

A Current Ratio of 4.74 indicates that CGEN has no problem at all paying its short term obligations.
CGEN's Current ratio of 4.74 is in line compared to the rest of the industry. CGEN outperforms 54.86% of its industry peers.
CGEN has a Quick Ratio of 4.74. This indicates that CGEN is financially healthy and has no problem in meeting its short term obligations.
CGEN's Quick ratio of 4.74 is in line compared to the rest of the industry. CGEN outperforms 56.19% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.74
Quick Ratio	4.74

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for CGEN have decreased strongly by -1600.00% in the last year.
The Revenue for CGEN has decreased by -88.47% in the past year. This is quite bad
Measured over the past years, CGEN shows a very strong growth in Revenue. The Revenue has been growing by 66.84% on average per year.

EPS 1Y (TTM)-1600%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-800%

Revenue 1Y (TTM)-88.47%

Revenue growth 3Y66.84%

Revenue growth 5YN/A

Sales Q2Q%-88.96%

3.2 Future

Based on estimates for the next years, CGEN will show a very negative growth in Earnings Per Share. The EPS will decrease by -17.74% on average per year.
CGEN is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -2.74% yearly.

EPS Next Y-9.65%

EPS Next 2Y-16.8%

EPS Next 3Y-1.49%

EPS Next 5Y-17.74%

Revenue Next Year-84.63%

Revenue Next 2Y-36.19%

Revenue Next 3Y-13.57%

Revenue Next 5Y-2.74%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CGEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.